Q2 revenue rises 7.4%, but property sale masks core loss

Going ConcernEmphasis Of MatterEbitda Margin ExpansionExceptional ItemResults RestatedResults View source PDF Explain this filing

INDOCO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.0%Reaction day

₹219.10

prior close

₹225.10

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.7%-1.7% vs market

Pharmaceuticals peers, median of 173sector+2.0%-1.9% vs sector

On the reaction day the stock moved 1.7 pts less than Nifty Microcap 250 and 1.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+4.4

10m

+2.6

15m

+2.2

30m

+0.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.0+1.7-1.7+2.0-1.9

Next day

-2.2+1.8-4.0+2.6-4.9

-4.6+2.5-7.0+2.7-7.3

-4.2pendingpending+2.0-6.2

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The board approved unaudited quarter and half-year results for September 2026. Consolidated revenue rose 7.4% year on year to Rs 507 crore; half-year EBITDA margin rose to 9% from 6.7%. Profit before exceptional items and tax was a Rs 23 crore loss. A Rs 37 crore property-sale gain and Rs 51 lakh trademark income produced Rs 19 crore profit. Auditors gave an unmodified opinion but flagged subsidiary negative net worth and going-concern risk.

Likely market impact

Revenue and margin gains help, but one-off gains masked a core loss. Subsidiary going-concern uncertainty may weigh on sentiment.